
|Videos|March 27, 2014
An Overview of the BR-002 Trial in Breast Cancer
Author(s)Julia White, MD
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the BR-002 trial, which will evaluate the rate of complete tumor ablation of breast cancers that are less than or equal to 2 centimeters.
Advertisement
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the BR-002 trial, which will evaluate the rate of complete tumor ablation of breast cancers that are less than or equal to 2 centimeters.
Clinical Pearls:
- This trial seeks to confirm that a local intervention does not change the outcome of a patient
- Participants of the trial will be randomized to ablation or standard treatment
- Women are only qualified for the trial if they are responding to chemotherapy or are in their first line of chemotherapy​
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
3
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
4
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
5







































